3388-79-2 Usage
Description
2-PIPERAZIN-2-YL-ETHANOL, with the molecular formula C6H14N2O, is a chemical compound derived from piperazine. It is recognized for its vasodilatory and cardiovascular properties, which contribute to its utility in the medical field. Additionally, it serves as a versatile solvent and additive in cosmetic and personal care products, although it requires careful handling due to potential harmful effects if misused.
Uses
Used in Pharmaceutical Industry:
2-PIPERAZIN-2-YL-ETHANOL is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of drugs with vasodilatory and cardiovascular effects, aiding in the treatment of different medical conditions.
Used in Chemical Synthesis:
As a derivative of piperazine, 2-PIPERAZIN-2-YL-ETHANOL is utilized as a building block in the creation of diverse organic compounds, expanding its applications across various chemical synthesis processes.
Used in Cosmetic and Personal Care Products:
2-PIPERAZIN-2-YL-ETHANOL is used as a solvent and additive in cosmetic formulations for its ability to dissolve various substances and enhance the performance of personal care products, while ensuring safety and efficacy in their applications.
Used in Research and Development:
In the scientific community, 2-PIPERAZIN-2-YL-ETHANOL is employed in research and development for studying its properties and potential applications, furthering the understanding of its role in chemical and medical fields.
Check Digit Verification of cas no
The CAS Registry Mumber 3388-79-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,3,8 and 8 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 3388-79:
(6*3)+(5*3)+(4*8)+(3*8)+(2*7)+(1*9)=112
112 % 10 = 2
So 3388-79-2 is a valid CAS Registry Number.
3388-79-2Relevant articles and documents
TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES
-
Paragraph 0275-0277, (2022/02/06)
The present disclosure relates to methods for the treatment or prevention of cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein. The present disclosure also relates to methods for reducing risk of developing cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein.
INHIBITORS OF KRAS G12C
-
Page/Page column 225, (2015/04/28)
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS
-
, (2008/06/13)
The use of a compound of formula (I) 1 or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O)2, or NR6 where R6 is hydrogen or C1-6 alkyl,; R5 is an optionally substituted 5-membered heteroaromatic ring, R1, R2 ,R3, R4 are independently selected from various specified moieties, in the preparation of a medicament for use in the inhibition of aurora 2 kinase. Certain compounds are novel and these, together with pharmaceutical compositions containing them are also described and claimed
